📰 Erik Manting News
Page 3 - Erik Manting News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Erik Manting. Real-time updates on events, politics, business and more.
August 31, 2023
As previously announced Mendus AB has carried out a capital raise whereby 472,953,859 new shares were issued in a rights issue and 187,500,000 new shares were issued in a directed issue. As a...
June 19, 2023
POSITIVE RECOMMENDATION BY COMMITTEE FOR ADVANCED THERAPIES CONFIRMS QUALITY OF THE MANUFACTURING PROCESS AND PRECLINICAL DATA SUBMITTED Mendus AB , a biopharmaceutical company focused on... | June 19, 2023
June 8, 2023
08.06.2023 - THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, ...
June 8, 2023
The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Extraordinary General Meeting (“EGM”) on Monday, 10...
June 8, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announces that it has entered into a manufacturing alliance with NorthX Biologics AB . NorthX is a... | June 8, 2023
May 25, 2023
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation...
May 12, 2023
At the annual general meeting of Mendus AB , reg. no. 556629-1786, on 12 May 2023 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the... | May 12, 2023
May 11, 2023
MENDUS TO PRESENT UPDATES ON IMMUNOMONITORING DATA FROM ADVANCE II TRIAL AND PROGRESS ON THE DEVELOPMENT OF ITS NK CELL THERAPY PROGRAM Mendus AB , a biopharmaceutical company focused on... | May 11, 2023
April 19, 2023
VIDIDENCEL INDUCES DURABLE VACCINE-INDUCED T-CELL RESPONSES IN THE MAJORITY OF PATIENTS Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today... | April 19, 2023
April 6, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has agreed with Negma Group Ltd to redeem the remainder of the first... | April 6, 2023